Liver Disease
Conference Coverage
Three-drug regimen shows promise for refractory primary biliary cholangitis
VIENNA – Combining ursodeoxycholic acid, obeticholic acid, and bezafibrate showed efficacy and tolerability for the toughest cases.
From the Journals
HCC linked to mitochondrial damage, iron accumulation from HCV
Mitochondrial damage and iron accumulation from HCV are linked to the development of hepatocellular carcinoma.
Conference Coverage
Blunted cardiac reserve strongly predicts incident hepatorenal syndrome
VIENNA – Cirrhotic patients with end-stage liver disease and a blunted cardiac response to dobutamine had a high...
From the AGA Journals
MicroRNA-375 may be key to fibrolamellar carcinoma
Overexpression of microRNA-375 in a fibrolamellar carcinoma cell line suppressed cell migration and proliferation, which hints at therapeutic...
Conference Coverage
Liver steatosis common in English young adults
VIENNA – Screening of more than 4,000 English young adults found a steatosis prevalence of 21%, and that severity was linked with obesity.
Video
Obeticholic acid reversed NASH liver fibrosis in phase 3 trial
VIENNA – Phase 3 trial results showed obeticholic acid, already FDA approved, is the first drug to reverse liver fibrosis in NASH patients.
Video
Research coalition issues plan for curing hepatitis B virus
VIENNA – More than 250 million people have hepatitis B virus infection, and no cure exists. Researchers published a strategy to fix this.
From the Journals
An HCV-infected population showed gaps in HBV testing, vaccination, and care
Conference Coverage
Future of NASH care means multiple targets, multiple providers, expert says
PHILADELPHIA – While current options are limited, newer treatments targeting different aspects of NASH pathogenesis could improve long-term...
From the Journals
Novel microbiome signature may detect NAFLD-cirrhosis
The microbial biomarker showed strong diagnostic accuracy for identifying cirrhosis in patients with NAFLD.